More than two million South Africans are living with diabetes, yet for many, the cost of treatment remains a major challenge. Now, a new partnership aims to make one of the world's most widely used diabetes medicines more accessible. Novo Nordisk has announced the launch of an authorised copy of semaglutide in South Africa, offering patients a more affordable treatment option without changing the medicine itself.
Unlike generic or compounded alternatives, an authorised copy is produced by the same manufacturer using the same active ingredient, manufacturing process and injection device as the original medicine, while meeting the same regulatory standards. To further unpack we are joined on the line by Sara Norcross, General Manger of Novo Nordisk South Africa

What changing shopping habits mean for the future of fashion retail
10:33

The family name debate challenging long held ideas about masculinity and heritage in Kenya
16:09

The lasting impact of absent or emotionally distant parents on adult relationships
16:19